On May 22, 2025, AN2 Therapeutics, Inc. held its annual stockholders' meeting with 79.50% of shares present, electing three directors and ratifying PricewaterhouseCoopers as its auditor for 2025. Votes showed Eric Easom received 13,983,213 for his election, while the firm appointment was ratified with 23,736,942 votes in favor.